Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent axes 93% of staff to preserve cash

This article was originally published in Clinica

Executive Summary

In a move to conserve its finances, drug-eluting stent specialist Xtent is set to cut 112 employees by March 23 2009. These cuts would represent a 93% reduction in its total employment base of 121 members of staff. The Menlo Park, California-based company is also enlisting the help of an unnamed investment bank in order to identify strategic alternatives, which may include the sale of some of its assets, or a merger or acquisition deal. The firm’s president and CEO, Gregory Casciaro, said that Xtent was reducing its activities to “a critical minimum” in a bid to boost shareholder value – the company’s shares having been trading at under $1.00 since November 2008. Last year, Xtent cut 73 of its staff in order to minimise expenses (see Clinica No 1315, p 14).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel